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The compound can be administered alone, combined with
an excipient, co-administered with a second drug having a
similar or synergistic effect. The compound is administered
subcutaneously, intramuscularly, intravenously,
5 transdermally, orally, intranasally, intrapulmonary or rectally. The use of cis-2,6-disubstituted piperidines and derivatives thereof in treating diseases or pathologies of the CNS
CROSS-REFERENCED TO RELATED
is implicated. In particular, the treatment of dependencies of
APPLICATIONS
such drugs as cocaine, amphetamine, caffeine, nicotine,
This application is a Divisional of application Ser. No.
phencyclidine, opiates, barbiturates, benzodiazepines,
09/628,557 filed Jul. 28, 2000, now U.S. Pat. No. 6,455,543 10 canabinoids, hallucinogens, and alcohol is implicated. Also,
issued Sep. 24, 2002, which claims the benefit of Provisional
the treatment of eating disorders such as obesity is impliApplication No. 60/146,144 filed Jul. 30, 1999.
cated.
In a preferred aspect of the invention, the method of
FIELD OF THE INVENTION
treatment reduces an individual's desire for the drug of
15
The present invention relates to lobeline analogs, specifiabuse or for food by at least one day, but it is also preferred
cally cis-2,6-disubstituted piperidines, and their method of
that the treatment method further comprise administering
use in the treatment of diseases and pathologies of the
behavior modification counseling to the individual.
central nervous system (CNS), the treatment of drug abuse
Although the compound of the present invention is contemand withdrawal therefrom as well as to the treatment of
plated primarily for the treatment of drug abuse and witheating disorders such as obesity.
20 drawal and for eating disorders, other uses are also suggested by the studies discussed herein. Thus, cognitive
BACKGROUND OF THE INVENTION
disorders, brain trauma, memory loss, psychosis, sleep
Alpha-Lobeline (lobeline), a lipophilic nonpyridino, alkadisorders, obsessive compulsive disorders, panic disorders,
loidal constituent of Indian tobacco, is a major alkaloid in a
myasthenia gravis, Parkinson's disease, Alzheimer's
family of structurally-related compounds found in Lobelia 25 disease, schizophrenia, Tourette's syndrome, Huntington's
inflata. Lobeline has been reported to have many nicotine
disease, attention deficit disorder, hyperkinetic syndrome,
like effects, including tachycardia and hypertension (Olin et
chronic nervous exhaustion, narcolepsy, motion sickness
al., 1995), hyperalgesia (Hamann et al., 1994) and improveand depression, and related conditions are considered to be
ment of learning and memory (Decker et al., 1993). Lobeline
susceptible to treatment with a compound of the present
has high affinity for nicotinic receptors (Lippiello et al., 30 invention.
1986; Broussolle et al., 1989). However, no obvious strucAs shown by the results of the studies described herein,
tural resemblance of lobeline to nicotine is apparent and
lobeline analogs are found to be effective in inhibiting
structure function relationships between S(-)-nicotine and
uptake of extracellular DA by cells of the CNS. Some of
lobeline do not suggest a common pharmacophore (Barlow
these analogs are also nicotinic receptor antagonists. Either
et al., 1989). Also, differential effects of lobeline and nico35 or both mechanisms can thereby work to alter the distributine suggest that these drugs may not be active through a
tion of the intracellular DA pools and as a result alter
common CNS mechanism, even though lobeline has been
extracellular DA concentration.
considered a mixed nicotinic agonist/antagonist.
As used herein the term "lobeline" refers to a compound
Lobeline evokes dopamine (DA) release from rat striatal
having the general chemical formula 2-[6-(~
slices. However, lobeline evoked DA release is neither
hydroxyphenethyl)-1-methyl-2-piperidy 1]-acetophenone.
dependent upon extracellular calcium nor is it sensitive to 40 The term "lobeline analogs" and equivalents thereof as used
mecamylamine, a noncompetitive nicotinic receptor antagoherein, refers to chemical derivatives of lobeline obtained by
nist. Thus, lobeline evoked DA release occurs via a different
oxidation or reduction of lobeline, others obtained by esterimechanism than does nicotine to evoke DA release (Teng et
fication of lobeline and redox derivatives, as well as various
al., 1997, 1998; Clarke et al., 1996). In this respect, lobeline
substitutions at the N-position of the piperidinyl moiety.
also inhibits DA uptake into rat striatal synaptic vesicles via 45
an interaction with the dihydrotetrabenazine (DTBZ) site on
DETAILED DESCRIPTION OF THE
vesicular monoamine transporter-2 (VMAT2), thus increasINVENTION
ing the cytosolic DA available for reverse transport by the
The 2,6-disubstituted piperidine lobeline analogs of the
plasma membrane transporter (DA1) (Teng et al., 1997,
1998). Thus, lobeline interacts with nicotinic receptors and 50 present invention include those contemplated by the following formula (I), without regard to chirality:
blocks nicotine-evoked DA release, but also interacts with
DA transporter proteins to modify the concentration of DA
(I)
in the cytosolic and vesicular storage pools, thereby altering
subsequent dopaminergic neurotransmission.

CIS-2,6-DISUBSTITUTED PIPERIDINES FOR
THE TREATMENT OF PSYCHOSTIMULANT
ABUSE AND WITHDRAWAL, EATING
DISORDERS, AND CENTRAL NERVOUS
SYSTEM DISEASES AND PATHOLOGIES

SUMMARY OF THE INVENTION
The present invention is directed to a method of treating
an individual who suffers from a disease or pathology of the
central nervous system (CNS) or for treating an individual
for drug dependence or withdrawal for drug dependence.
The method comprises of administering to the individual an
effective amount of a cis-2,6-substituted piperidino
compound, i.e., a lobeline analog, including pharmaceutically acceptable salts of such compounds thereof. As used
herein, an "effective amount" refers to an amount of a drug
effective to reduce an individual's desire for a drug of abuse
or for food, or for alleviating at least one of the symptoms
of the disease or pathological symptom of a CNS pathology.
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wherein:
n is zero or an integer in the range from 1 to 3;
X 1 - Y 1 and X 2 - Y 2 are the same or are independently
different from one another and represent a saturated carboncarbon bond, a cis-carbon-carbon double bond, a transcarbon-carbon double bond, a carbon-carbon triple bond; a
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4

saturated sulfur-carbon bond, a saturated selenium-carbon
bond, an oxygen-carbon bond, a saturated nitrogen-carbon
bond, a N-alkyl substituted saturated nitrogen-carbon bond
where said alkyl is a lower straight chain or branched alkyl,
a nitrogen-carbon double bond, or a nitrogen-nitrogen
double bond;
R1 and R 4 are the same or are independently different
from one another and represent hydrogen or a lower straight
chain or branched alkyl or R 1 and R 4 together form a ring
including a -CH 2- , -CH 2CH 2- , -CH 2CH 2-CH 2- ,
-cis-CH=CH, -cis-CH 2-CH=CH- or -cis-CH 2=CHCH2- moiety;
R2 and R3 are the same or are independently different
from one another and represent a saturated or unsaturated
hydrocarbon ring; a nitrogen containing heterocyclic moiety; an oxygen containing heterocyclic moiety; a sulfur
containing heterocyclic moiety; a selenium containing heterocyclic moiety; a mixed heterocyclic moiety containing at
least two atoms selected from the group consisting of
nitrogen, oxygen and sulfur; and an ortho, meta or parasubstituted benzene;
with the proviso that when n=O, R 2 and R3 are unsubstituted phenyl groups, and X 1 -Y1 and X2-Y2 are saturated
carbon-carbon bonds, Y 1 cannot be CH 2, CHOH or C=O,
and Y 2 cannot be CH 2, CHOH, or C=O.
It is preferred that when R 2 and/or R3 is a saturated
hydrocarbon ring, the ring includes, but is not limited to,
cyclobutane, cyclopentane, cyclohexane, cycloheptane or
cyclooctane, including all possible substitution patterns,
geometric and stereoisomers, racemic, diastereomeric and
enantiomeric forms thereof.
It is further preferred that when R 2 and/or R3 is an
unsaturated hydrocarbon ring, the ring includes, but is not
limited to, benzene, cyclopentene, cyclohexene,
cycloheptene, cyclooctene or cyclopentadiene, including all
possible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric and enantiomeric forms thereof.
It is further preferred that when R 2 and/or R3 is a nitrogen
containing heterocyclic moiety, the moiety includes, but is
not limited to, azetine, piperdine, piperazine, pyrazine,
pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine,
hexa-hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3triazole, 1,2,4-triazole, pyridine or pyridazine, including all
possible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric and enantiomeric forms thereof.
It is further preferred that R 2 and/or R3 is an oxygen
containing heterocyclic moiety, the moiety includes, but is
not limited to, furan, tetrahydrofuran, 2,5-dihydrofuran,
pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4oxathinin, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.
It is further preferred that when R 2 and/or R3 is a sulfur
containing heterocyclic moiety, the moiety includes, but is
not limited to, thietane, thiophene, thiophane, 2,5dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3dithane, 1,4-dithiane, or thiopyranylium, including all
possible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric and enantiomeric forms thereof.
It is further preferred that when R 2 and/or R3 is a selenium
containing heterocyclic moiety, the moiety includes, but is
not limited to, selenophene, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.
It is further preferred that when R 2 and/or R3 is a mixed
heterocyclic moiety, the moiety includes, but is not limited

to, thiazolidine, thiazole and oxazin, including all possible
substitution patterns, geometric and stereoisomers, racemic,
diastereomeric and enantiomeric forms thereof.
The substituted benzene includes at least one substituent,
where the substituent is selected from, but is not limited to,
the group consisting of methyl, ethyl, propyl, isopropyl,
butyl, sec-butyl, isobutyl, amino, N-methylamino, N,Ndimethylamino, carboxylate, methylcarboxylate,
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate,
carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy,
cyano, aminomethyl, N -methylaminomethyl, N ,Ndimethylaminomethyl,
carboxamide,
N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl,
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl,
methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio,
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo,
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl,
ureido, azido, isocyanate, thioisocyanate, hydroxylamino
and nitroso.
It is preferred that when either X 1 - Y 1 or X2- Y 2 is a
saturated carbon-carbon bond, Y 1 or Y 2 represents CH 2,
CH-OH, CHO-alkyl where said alkyl is a lower straight
chain or branched alkyl, CH-OS0 2-C 6H5 , CH-OS0 2p-C6H4CH3, CH-SH, C6H5 -SH, CH-S-alkyl where said
alkyl is a lower straight chain or branched alkyl, CH-N0 2,
CH-CF3, CH-NHOH, CH-OCHO, CH-F, CH-Cl,
CH-Br, CH-I, CH-NH 2, CH-NH-alkyl where said
alkyl is a lower straight chain or branched alkyl, CH-N
(alkyl) 2 where said alkyl is a lower straight chain or
branched alkyl, CH-OCONH 2, CH-OCONH-alkyl
where said alkyl is a lower straight chain or branched alkyl,
CH-OCON(alkyl) 2 where said alkyl is a lower straight
chain or branched alkyl, CH-N3, C=O or C=S; CH-0aryl such as a phenyl, ortho-, meta-, or para-substituted
phenyl where the substituent is as described above; or a
hydrocarbon or hetercyclic ring such as pyridyl, furanyl,
naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-triazole,
1,2,4-triazole, imidazoline, pyrimidine, pyridazine or
triazine, including all possible substitution patterns, diastereomeric and enantiomeric forms thereof.
The lower straight or branched alkyl can be an alkyl group
containing one to seven carbon atoms. The preferred alkyl
groups are methyl and ethyl.
The above 2,6-substituted piperidino analogs are preferred in their cis-geometrical isomeric forms, or in their
trans geometric forms, including all possible geometric,
racemic, diasteriomeric, and enantiomeric forms thereof.
The above cis-2,6-disubstituted piperidines as well as
analogs thereof can be administered in their free base form
or as a soluble salt. Whenever it is desired to employ a salt
of a cis-2,6-substituted piperidine or its analog, it is preferred that a soluble salt be employed. Some preferred salts
include hydrochloride, hydrobromide, nitrate, sulfate,
phosphate, tartrate, galactarate, fumarate, citrate, maleate,
glycolate, malate, ascorbate, lactate, aspartate, glutamate,
methanesulfonate, p-toluenesulfonate, benzenesulfonate,
salicylate, proprionate, and succinate salts. The above salt
forms may be in some cases hydrates or solvates with
alcohols and other solvents.
A pharmaceutical composition containing a compound of
the invention is also contemplated, which may include a
conventional additive, such as a stabilizer, buffer, salt,
preservative, filler, flavor enhancer and the like, as known to
those skilled in the art. Representative buffers include
phosphates, carbonates, citrates and the like. Exemplary
preservatives include EDTA, EGTA, BHA, BHT and the
like. A composition of the invention may be administered by

5

10

15

20

25

30

35

40

45

50

55

60

65

US 6,943,177 B2
5

6

constants (Ki values) ranging from 0.0043 ,uM to >100 ,uM.
inhalation, i.e., intranasally as an aerosol or nasal formulation; topically, i.e., in the form of an ointment, cream or
Five of these compounds were in the range of 4--160 nM.
lotion; orally, i.e., in solid or liquid form (tablet, gel cap,
Three of these compounds were in the range of 0.93-14 ,uM.
time release capsule, powder, solution, or suspension in
One compound was >100 ,uM. The cis-2,6-disubstituted
aqueous or non aqueous liquid; intravenously as an infusion 5 piperidino derivatives listed in Table 1 were also assayed for
or injection, i.e., as a solution, suspension or emulsion in a
inhibition of DAT activity, i.e., inhibition of [3 H]DA uptake
pharmaceutically acceptable carrier; transdermally, e.g., via
into the dopaminergic presynaptic terminal. Nine coma transdermal patch; rectally as a suppository and the like.
pounds were evaluated and afforded inhibition constants (Ki
Generally, the pharmacologically effective dose of a
values) ranging from 0.08 ,uM to 54 ,uM.
present compound is in the amount ranging from about
Removal of both functionalities of the lobeline molecule
1x10- 5 to about 1 mg/kg body weight/day. The amount to be 10
resulted in loss of affinity for the nicotinic receptor and a
administered depends to some extent on the lipophilicity of
100-fold more potent inhibition of the dopamine transporter
the specific compound selected, since it is expected that this
compared with lobeline. Removal of either the hydroxyl
property of the compound will cause it to partition into fat
group or the keto group of lobeline resulted in a 50-fold loss
deposits of the subject. The precise amount to be administered can be determined by the skilled practitioner in view 15 of affinity for the nicotinic receptor. Interestingly, the
ketoalkene analog inhibited DAT 10-fold more potently than
of desired dosages, side effects and medical history of the
lobeline, whereas lobelanidine inhibited DAT equipotently
patient and the like.
The cis-2,6-disubstituted piperidino analogs of the present
compared to lobeline. Conversion of the hydroxy group of
invention exhibit selectivity for either neuronal nicotinic
lobeline to a bulky tosyloxy group reduced the affinity of the
acetylcholine receptors and/or the dopamine transporter 20 nicotinic receptor by only 3-fold, but did not alter the
protein (DAT). The derivatives that are active towards the
interaction with the DA transporter. The hydroxyalkene had
nicotinic receptor generally do not interact with the DAT,
a similar potency with the meso-transdiene (the most potent
and those that interact with the DAT show only modest
compound) in the DA uptake assay, but had 1000-fold lower
nicotinic receptor activity.
affinity for the nicotinic receptor. Also, the completely
25 defunctionalized lobeline molecule and the hydroxyalkane
TABLE 1
analog were both less potent than the meso-transdiene in
inhibiting DA uptake into striatal synaptosomes. This data
(II)
indicates that appropriate structural modification of the
lobeline molecule affords compounds in which the interac30 tion with DAT is enhanced. Furthermore, in one compound,
i.e., the meso-transdiene, the nicotinic receptor interaction
has been eliminated and the compound is thus selective for
inhibition of DAT.
The invention will now be discussed by certain examples
35 that illustrate but do not limit the invention.
Ki (uM)
Ki (uM)
Compound
1.

2.
3.

4.
5.
6.

7.

8.
9.

X ~ X 2 ~ CH2
Y' ~ c~o
Y 2 ~ (S)---CHOH
X 1 ~ X 2 ~ Y 1 ~ Y 2 ~ CH2
X 1 ~ X 2 ~ CH2
Y' ~ c~o
Y 2 ~ (S)---CHOS0 2---C6 H 4 -p-CH3
X 1 ~ X 2 ~ CH2
Y' ~Y 2 ~ c~o
X', Y 1 ~ X 2, Y 2 ~ trans CH~CH
X 1 ~ CH2
Y' ~ c~o
X 2, Y 2 ~ trans CH~CH
X 1 ~ X 2 ~ CH2
Y 1 ~ (S)---CHOH
Y 2 ~ (R)---CHOH
X 1 ~ X 2 ~ Y 2 ~ CH2
Y 1 ~ (RS)---CHOH
X 1 ~ CH2
Y 1 ~ (S)---CHOH
X 2, Y 2 ~ trans CH~CH
1

[3H]-Nicotine
Binding Assay

0.0043

[ 3H]-Dopamine
Uptake Assay

EXAMPLE 1

45

Cis-2, 6 -di-trans-styry!piperidine
40

14.3
0.0041

3.0
39

11

25

>100
0.13

0.93

0.8
3.0

45

54
50

0.16

8.9

4.2

1.3

55

The nine cis-2,6-disubstituted piperidino derivatives
listed in Table 1 have the chemical structure of formula (II).
They were assayed for nicotinic receptor interaction and
inhibition of DAT activity. The cis-2,6-disubstituted piperidino analogs of the present invention exhibit selectivity for
either neuronal nicotinic acetylcholine receptors and/or the
dopamine transporter protein (DAT). The derivatives that
are active towards the nicotinic receptor generally do not
interact with the DAT, and those that interact with the DAT
show only modest nicotinic receptor activity.
The nine compounds in Table 1 were evaluated in the high
affinity [3 H]nicotine binding assay and afforded inhibition

1.00 g (2.95 mmol) oflobelanidine was dissolved in 15 ml
of 85% H 3 P0 4 and allowed to stir overnight at 60° C. The
reaction mixture was taken up in H 2 0 and made basic with
solid K 2 C0 3 (pH-8). The pH was adjusted by the addition
of solid NaOH (pH-10). The aqueous solution was extracted
three times with 15 ml of EtOAc. The organic layers were
combined and dried over anhydrous MgS0 4 . The salts were
removed via filtration and solvent removed by rotary evaporation affording 0.70 g of crude product. This compound was
recrystallized from MeOH affording 0.60 g of pure cis-2,6di-trans-styrylpiperidine. Percent yield=78.6%
Mp=139-141 o C. 1 H NMR (300 MHz, CDC1 3 ) d: 1.40-1.80
(m, 6H), 2.23 (s, 3H), 2.50--2.64 (t, 2H), 6.04-6.20 (dd, 2H),
6.39-6.50 (d, 2H) and 7.10-7.38 (m, 10H); 13 C NMR
(CDC1 3 ) d: 23.75, 33.56, 42.32, 68.36, 126.26, 127.38,
128.61, 130.52, 133.89 and 137.13 ppm.
EXAMPLE 2
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Cis-2S,6R,8S-2-[ 6-~-para
toluenesulfonyloxyphenethyl)-1-methyl-2piperidyl]-acetophenone
1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved
in 25 ml of pyridine and was added dropwise to a solution
(cooled to 0° C.) containing 0.60 g (3.14 mmol) of
p-toluenesulfonyl chloride dissolved in 15 ml of pyridine.
After addition, the reaction was allowed to stir for 2 hours
and then poured into 50 ml of ice-cold water and the mixture

US 6,943,177 B2
7

8

was stirred for an additional two hours. The aqueous solution was extracted three times with 25 ml of EtOAc. The
organic layers were combined and dried over anhydrous
Na 2 S0 4 . The salts were removed by filtration and the
solvent was removed by rotary evaporation affording 450
mg of a pink-colored compound. The product was recrystallized from acetone yielding 300 mg of the product.
Percent yield=21.6% mp=169.1-171.0° C. 1 H NMR (300
MHz, CDC1 3 ) ll: 1.30-1.98 (m, 6H), 2.20 (s, 3H), 2.63-2.74
(d, 3H), 2.95-3.20 (m, 2H), 3.61-3.78 (d, lH), 3.83-4.12
(m, 2H), 4.50-4.72 (m, lH), 4.80-4.90 (d, lH), 6.90-7.00
(d, 2H), 7.10-7.50 (m, 8H), 7.50-7.60 (d, 2H), 7.80--7.90 (d,
2H) and 9.85 (s, lH); 13 C NMR (CDC13 ) ll: 21.16, 22.25,
23.32, 23.55, 27.35, 38.29, 40.18, 40.07, 60.79, 63.69,
71.05, 125.56, 125.76, 127.39, 128.28, 128.44, 128.69,
128.77, 133.67, 133.96, 135.87, 140.03, 141.98, 144.47 and
195.21 ppm.

and placed into a Parr hydrogenation apparatus with 0.10 g
of 10% Pd-on-Carbon. After removal of air, hydrogen gas
was introduced until a pressure of 40 psig was reached. The
reaction was allowed to proceed for 48 hrs. The Pd catalyst
was removed through filtration with Celite, and ethanol was
removed by rotary evaporation to afford 0.30 g of a yellow
oil. The compound was purified by silica gel chromatography eluting with EtOAc to afford 0.25 g of the product. The
yield was 50.0%. 1 H NMR (300 MHz, CDC1 3 ) ll: 0.70-0.90
(m, 6H), 1.18 (s, 3H), 1.40-1.90 (m, 6H), 2.44-2.56 (m,
2H), 4.56-4.60 (dd, lH) and 7.04-7.30 (m, 10H); 13 C NMR
(CDC1 3 ) ll: 25.77, 29.24, 29.38, 29.42, 29.46, 29.68, 31.44,
35.93, 39.07, 74.64, 125.50, 125.85, 127.42, 128.17, 128.35,
128.37, 142.85 and 144.91 ppm.
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EXAMPLE 6
High Affinity [3 H]Nicotine Binding Assay

EXAMPLE 3
Cis-2S,6R-N-methyl-6-phenacyl-2-transstyrylpiperidine
1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved
in 15 ml of 85% H3 P0 4 and the solution was allowed to stir
for 24 hrs at 50° C. Phosphoric acid was then neutralized
with K 2 C0 3 , and a little ice cold H 2 0 was added to dissolve
the salts. The aqueous solution was extracted with ethyl
acetate (20 mlx3). The organic layers were combined and
dried with anhydrous MgS0 4 . The salts were removed by
filtration and the solvent was removed via rotary
evaporation, affording 0.80 g of a gummy solid, which
contained mainly the trans isomer. Percent yield=84.6%. 1 H
NMR (300 MHz, CDC1 3 ) 1.15-1.60 (m, 6H), 2.02 (s, 3H),
2.47-2.71 (m, 3H), 3.16-3.34 (dd, lH), 5.80-6.00 (dd, lH),
6.18-6.28 (d, lH), and 6.90--7.38 (m, 8H) and 7.64--7.80 (d,
2H); 13 C NMR (CDC1 3 ) 23.52, 32.56, 33.17, 40.52, 44.02,
59.62, 68.08, 126.00, 127.15, 127.92, 128.36, 128.44,
130.29, 132.91, 133.91, 136.95, 136.99 and 198.83 ppm.
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EXAMPLE 4
Cis-10R,2S,6R- and Cis-10S,2S,6R-N-methyl-6-[1(2-hydroxy-2-pheny1)-ethyl ]-2-trans-styry!piperidine
In a 250 ml round bottom flask was added 0.80 g of
cis-2S,6 R-N-meth y1-6-p he nacy1-2-trans-s tyry lpipe ridine,
and 50 ml of ethanol. Sodium borohydride was added until
all of the starting material was consumed (determined by
TLC). The solution was cooled to 0° C. and acetone was
added in small portions to quench the reaction. The solvents
were evaporated to dryness and water was added precipitating 0.75 g of an off-white crystalline solid (1:1) mixture
of diastereomers, which was purified on silica eluting with
75:25 (CHCl 3 /EtOH). The yield of the product (a mixture of
diastereomers) was 93.4%. 1 H NMR (300 MHz, CDC13 ) ll:
1.17-2.06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50-6.20
(m, 4H), 2.70--3.20 (m, 4H), 4.78-4.80 (dd, lH), 5.04-5.14
(dd, lH), 5.96-6.20 (m, 2H), 6.32-6.42 (dd, 2H) and
7.04-7.34 (m, 20H); 13 C NMR (CDC13 ) ll: 23.69, 24.15,
26.74, 29.68, 33.26, 39.94, 41.10, 41.41, 62.93, 63.00,
65.62, 68.32, 71.76, 73.90, 125.46, 126.15, 126.19, 126.83,
127.01, 127.37, 128.16, 128.23, 128.50, 130.58, 132.61,
133.85, 136.83, 136.95, 145.32 and 145.45 ppm.
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EXAMPLE 7

EXAMPLE 5
Cis-2S,6R-N -methyl-6-[1-(2-hydroxy-2-phenyl)
ethy1]-2-pheny lethy!piperidine
0.50 g (1.55 mmol) of cis-2S,6R-N-methyl-6-phenacyl2-trans-styrylpiperidine was dissolved in 50 ml of ethanol

The ability to displace S(-)[ 3 H]NIC binding from rat
striatal membranes to assess interaction with the a4~2
subtype was determined. The [ 3 H]NIC binding assay was
performed according to previously published methods
(Romano et al., 1980; Marks et al., 1986; Crooks et al.,
1995). Striata from two rats were dissected, pooled and
homogenized with a Tekmar polytron in 10 vol of ice-cold
modified Krebs-HEPES buffer (in mM; 20 HEPES, 118
NaCl, 4.8 KCl, 2.5 CaC12 , 1.2 MgS0 4 , adjusted to pH to
7.5). The homogenate was incubated at 37° C. for 5 minutes
to promote hydrolysis of endogenous acetylcholine, and
centrifuged at 15,000 g for 20 minutes and the pellet was
resuspended in 10 vol of ice-cold distilled water and incubated at 37° C. for 5 minutes, followed by centrifugation at
15,000 g for 20 min. The pellet containing the striatal
membranes was resuspended in 10 vol of fresh ice-cold 10%
Krebs-HEPES buffer and incubated at 37° C. for 10 min
after which it was centrifuged at 15,000 g for 20 minutes.
The lafter sequence of resuspension, incubation and centrifugation was repeated. The pellet was frozen under fresh
Krebs-HEPES buffer and stored at -40° C. until assay. Upon
assay, the pellet was resuspended in Krebs-HEPES buffer,
incubated at 37° C. for 5 minutes and centrifuged at 15,000
g for 20 min. The final pellet was resuspended in 3.6 ml
ice-cold water which provides for approximately 200 jAg
protein/100 tAl aliquot. Competition assays were performed
in duplicate in a final volume of 200 tAl Krebs-HEPES buffer
containing 250 mM Tris buffer (pH 7.5 at 4° C.). Reactions
were initiated by addition of 100 tAl of membrane suspension
to 3 nM [3 H]NIC (50 tAl) and 1 of at least 9 concentrations
of analog (50 tAl). After 90 minutes incubation at 4° C.,
reactions were terminated by dilution of the samples with 3
ml of ice-cold buffer followed immediately by filtration
through a Whatman GF/B glass fiber filters (presoaked in
0.5% polyethyleneimine (PEl) using a Brandel Cell Harvester. Filters were rinsed 3x with 3 ml of ice-cold buffer,
transferred to scintillation vials and 5 ml scintillation cocktail added. Nonspecific binding was defined as binding in the
presence of 10 jAM NIC. For competition curves, the IC 50
values were corrected for ligand concentration (Cheng et al.,
1973).

[

65

3

H]Dopamine ([ 3 H]DA) Uptake Assay, Striatal
Synaptosomal Preparation

3
[ H]DA uptake was performed according to a modification of the previously reported methods (Dwoskin et al.,
1999). Striata were homogenized in 20 ml of ice-cold
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construction and operation shown and described, and
sucrose solution (0.32 M sucrose and 5 mM sodium
accordingly, all suitable modifications and equivalence
bicarbonate, pH 7.4) with 12 passes of a teflon-pestle
thereof may be resorted to, falling within the scope of the
homogenizer (clearance approximately 0.003 in). The
invention claimed.
homogenate was centrifuged at 2,000 g, 4° C. for 10 min.
The supernatant was centrifuged at 12,000 g, 4° C. for 20 5
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What is claimed is:
1. A method of treating an individual for dependence on
a drug of abuse or withdrawal from a drug of abuse
comprising administering to the individual an effective
amount of a cis-2,6-substituted piperidino compound or
pharmaceutically effective salt thereof comprising formula
(I):

12

straight chain or branched alkyl, C3 -C 6 cycloalkyl,
vinyl, allyl, C 4 -C 7 alkenyl, benzyl, phenylethyl,
N-methylamino, N,N-dimethylamino, carboxylate,
me th ylc arb o xyl ate,
e th ylc arb o xyla te,
5
propylc arb oxyla te, isop ropylc arb oxyla te,
carboxaldehyde, acetoxy, propionyloxy,
isopropionyloxy, cyano, aminomethyl,
N -methylaminomethy 1, N ,N -dimethylaminomethyl,
carboxamide, N-methylcarboxamide, N,N(I)
10
dimethylcarboxamide, acetyl, propionyl, formyl,
benzoyl, sulfate, methylsulfate, hydroxyl, methoxy,
ethoxy, propoxy, isopropoxy, thiol, methylthio,
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo,
trifiuoromethyl, propargyl, nitro, carbamoyl, ureido,
azido, isocyanate, thioisocyanate, hydroxylamino, and
15
nitroso.
2. The method of claim 1, wherein said drug of abuse is
selected from the group consisting of cocaine, amphetamine,
wherein:
caffeine, nicotine, phencyclidine, opiates, barbiturates,
X 1 -Y 1 and X2 -Y2 are the same or are independently 20 benzodiazepines, canabinoids, hallucinogens, and alcohol.
different from one another and represent a saturated
3. The method of claim 1, wherein said administering of
carbon-carbon bond, a cis-carbon-carbon double bond,
the compounds is performed subcutaneously,
a trans-carbon-carbon double bond, a carbon-carbon
intramuscularly, intravenously, transdermally, orally,
triple bond; a saturated sulfur-carbon bond, a saturated
intranasally, intrapulmonary or rectally.
selenium-carbon bond, an oxygen-carbon bond, a satu- 25
4. The method of claim 1, wherein said administering of
rated nitrogen-carbon bond, aN-alkyl substituted satuthe compound inhibits uptake of dopamine by cells of the
rated nitrogen-carbon bond where said alkyl is a lower
central nervous system of the individual.
straight chain or branched alkyl, a nitrogen-carbon
5. The method of claim 1, wherein said administering of
double bond, or a nitrogen-nitrogen double bond;
the compound inhibits binding of neurotransmitters or drugs
R1 and R 4 are the same or are independently different 30 to nicotinic receptors on cells of the central nervous system
of the individual.
from one another and represent hydrogen or a lower
straight chain or branched alkyl or R 1 and R 4 together
6. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane,
form a ring including a -CH 2 - , -CH 2 CH 2 - ,
-CH 2 CH 2 -CH 2 - , -cis-CH=CH, -cis-CH 2 cyclohexane, cycloheptane or cyclooctane.
7. The method of claim 1, wherein the unsaturated hydroCH=CH- or -cis-CH 2 =CH-CH 2 - moiety; and
35
carbon ring includes benzene, cyclopentene, cyclohexene,
R2 and R3 are the same or are independently different
cycloheptene, cyclooctene or cyclopentadiene.
from one another and represent a saturated or unsatur8. The method of claim 1, wherein the nitrogen containing
ated hydrocarbon ring; a nitrogen containing heterocyheterocyclic
moiety includes azetine, piperidine, piperazine,
clic moiety; an oxygen containing heterocyclic moiety;
a sulfur containing heterocyclic moiety; a selenium 40 pyrazine, pyrazole, pyrazolidine, imidazole imidazoline,
pyrimidine, hexa-hydropyrimidine, pyrrole, pyrrolidine,
containing heterocyclic moiety; a mixed heterocyclic
triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or
moiety containing at least two atoms selected from the
pyridazine.
group consisting of nitrogen, oxygen and sulfur; and an
9. The method of claim 1, wherein the oxygen containing
ortho, meta or para-substituted benzene;
45 heterocyclic moiety includes furan, tetrahydrofuran, 2,52
3
with the proviso that when R and R are unsubstituted
dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3phenyl groups and X 1 - Y 1 and X2 - Y 2 are saturated
dioxane or 1,4-oxathinin.
1
2
carbon-carbon bonds, Y and Y cannot be CHOR or
10. The method of claim 1, wherein the unsaturated sulfur
C=O, wherein R is hydrogen, lower alkyl, lower
containing heterocyclic moiety includes thietane, thiophene,
alkenyl, lower alkylcarbonyl, arylcarbonyl,
aralkylcarbonyl, lower alkoxycarbonyl, lower 50 thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2alkylamino-carbonyl, higher alkylcarbonyl or poly
dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium.
( alkyleneoxide)-carbonyl;
11. The method of claim 1, wherein the selenium conwith the further proviso that when R 2 and R3 are unsubtaining heterocyclic moiety is selenophene.
stituted phenyl groups or substituted phenyl groups 55
12. The method of claim 1, wherein the mixed heterocyhaving an alkyl, alkoxy, chlorine or CF 3 as substituents
clic moiety is thiazolidine, thiazole or oxazin.
1
1
2
2
and X -Y and X -Y are saturated nitrogen-carbon
13. The method of claim 1, wherein the substituted
bonds, X 1 and X2 cannot be C=O; and
benzene includes at least one substituent selected from the
1
1
2
2
with the further proviso that when X -Y and X -Y
group consisting of methyl, ethyl, propyl, isopropyl, butyl,
are saturated carbon-carbon bonds, X 1 and X2 cannot 60 sec-butyl, isobutyl, amino, N-methylamino, N,N1
2
be CH 2 or CH=CH, and Y and Y cannot be CH 2 or
dimethylamino, carboxylate, methylcarboxylate,
CH=CH, C=O or CHOH;
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate,
carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy,
with the further proviso that when X 1 -Y1 and X2 -Y2
are carbon-carbon double bonds, R 2 and R3 cannot be
cyano, aminomethyl, N -methylaminomethyl, N ,Nc arb o x am i d e ,
a saturated or unsaturated hydrocarbon ring with an 65 d i m e t h y 1a m i n o m e t h y 1,
N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl,
ortho-, meta- or para substituted moiety selected from
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl,
the group consisting of hydrogen, methyl, ethyl, C3 -C 7
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methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio,
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo,
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl,
ureido, azido, isocyanate, thioisocyanate, hydroxylamino
and nitroso.
14. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane,
cyclohexane, cycloheptane or cyclooctane; the unsaturated
hydrocarbon ring includes benzene, cyclopentene,
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene;
the nitrogen containing heterocyclic moiety includes
azetine, piperdine, piperazine, pyrazine, pyrazole,
pyrazolidine, imidazole imidazoline, pyrimidine, hexahydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen
containing heterocyclic moiety includes furan,
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran,
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin; the sulfur containing heterocyclic moiety includes thietane, thiophene,
thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium; the
selenium containing heterocyclic moiety includes selenophene; the mixed heterocycic moiety includes
thiazolidine, thiazole or oxazin; and the substituent for the
substituted benzene includes at least one member selected
from the group consisting of methyl, ethyl, propyl,
isopropyl, butyl, sec-butyl, isobutyl, amino,
N -methylamino, N,N -dimethylamino, carboxylate,
methylcarboxylate, ethylcarboxylate, propylcarboxylate,
isopropylcarboxylate, carboxaldehyde, acetoxy,
propionyloxy, isopropionyloxy, cyano, aminomethyl,
N -methylaminomethyl, N ,N -dimethylaminomethyl,
carboxainide, N -methylcarboxamide, N ,Ndimethylcarboxamide, acetyl, propionyl, formyl, benzoyl,
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy,
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro,
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl,
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate,
hydroxylamino, and nitroso.
15. The method of claim 1, wherein when either X 1 -Y1
or X2 -Y2 is a saturated carbon-carbon bond, Y 1 or Y 2
represents CH 2 , CH-OH, CHO-alkyl where said alkyl is a
lower straight chain or branched alkyl, CH-OS0 2 -C 6 H5 ,
CH-OS0 2 -p-C 6 H 4 CH 3 , CH-SH, C 6 H5 -SH, CH-Salkyl where said alkyl is a lower straight chain or branched
alkyl, CH-N0 2 , CH-CF 3 , CH-NHOH, CH-OCHO,
CH-F, CH-Cl, CH-Br, CH-I, CH-NH 2 , CH-NHalkyl where said alkyl is a lower straight chain or branched
alkyl, CH-N(alkyl) 2 alkyl where said alkyl is a lower
straight chain or branched alkyl, CH-OCONH 2 ,
CH-OCONH-alkyl where said alkyl is a lower straight
chain or branched alkyl, CH-OCON(alkyl) 2 where said
alkyl is a lower straight chain or branched alkyl, CH-N3 ,
C=O or C=S; CH-0-phenyl, substituted CH-0- phenyl where the substituent is at least one member selected
from the group consisting of methyl, ethyl, propyl,
isopropyl, butyl, sec-butyl, isobutyl, amino,
N -methylamino, N,N -dimethylamino, carboxylate,
methylcarboxylate, ethylcarboxylate, propylcarboxylate,
isopropylcarboxylate, carboxaldehyde, acetoxy,
propionyloxy, isopropionyloxy, cyano, aminomethyl,
N -methylaminomethyl, N ,N -dimethylaminomethyl,
carboxamide, N-methylcarboxamide, N,Ndimethylcarboxamide, acetyl, propionyl, formyl, benzoyl,
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy,
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro,

chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl,
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate,
hydroxylamino, and nitroso; or a hydrocarbon or heterocyclic ring comprising pyridyl, furanyl, naphthyl, thiazole,
selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole,
imidazoline, pyrimidine, pyridazine or triazine.
16. The method of claim 1, wherein the pharmaceutical
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate,
citrate, fumarate and tartrate salts of said compound.
17. The method of claim 15, wherein the pharmaceutical
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate,
citrate, fumarate and tartrate salts of said compound.
18. The method of claim 1, wherein said lower straight
chain or branched alkyl contains one to seven carbon atoms.
19. The method of claim 18, wherein said alkyl is methyl
or ethyl.
20. The method of claim 15, wherein said lower straight
chain or branched alkyl contains one to seven carbon atoms.
21. The method of claim 20, wherein said alkyl is methyl
or ethyl.
22. The method of claim 1, wherein said compound is
cis-2S,6R,8S-2-[ 6-~-para -toluenesulfonyloxyphenethyl)-1methyl-2-piperidyl]-acetophenone.
23. The method of claim 1, wherein said compound is
cis-2S,6R- N -me thy 1-6-[1-(2-hydroxy- 2-phenyl)ethyl ]-2phenylethylpiperidine.
24. A cis-2,6-substituted piperidino compound or pharmaceutically effective salt thereof comprising formula (I):
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60
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wherein:
X 1 - Y 1 and X2 - Y 2 are the same or are independently
different from one another and represent a saturated
carbon-carbon bond, a cis-carbon-carbon double bond,
a trans-carbon-carbon double bond, a carbon-carbon
triple bond; a saturated sulfur-carbon bond, a saturated
selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, aN-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower
straight chain or branched alkyl, a nitrogen-carbon
double bond, or a nitrogen-nitrogen double bond;
R 1 and R 4 are the same or are independently different
from one another and represent hydrogen or a lower
straight chain or branched alkyl or R 1 and R 4 together
form a ring including a -CH 2 - , -CH 2 CH 2 - ,
-CH 2 CH 2 -CH 2 - , -cis-CH=CH, -cis-CH 2 CH=CH- or -cis-CH 2 =CH-CH 2 - moiety; and
R 2 and R3 are the same or are independently different
from one another and represent a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocyclic moiety; an oxygen containing heterocyclic moiety;
a sulfur containing heterocyclic moiety; a selenium
containing heterocyclic moiety; a mixed heterocyclic
moiety containing at least two atoms selected from the
group consisting of nitrogen, oxygen and sulfur; and an
ortho, meta or para-substituted benzene;
with the proviso that when R 2 and R3 are unsubstituted
phenyl groups and X 1 -Y1 and X2 -Y2 are saturated
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carbon-carbon bonds, Y 1 and Y 2 cannot be CHOR or
sec-butyl, isobutyl, amino, N-methylamino, N,NC=O, wherein R is hydrogen, lower alkyl, lower
dimethylamino, carboxylate, methylcarboxylate,
alkenyl, lower alkylcarbonyl, arylcarbonyl,
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate,
aralkylcarbonyl, lower alkoxycarbonyl, lower
carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy,
alkylamino-carbonyl, higher alkylcarbonyl or poly 5 cyano, aminomethyl, N -methylaminomethyl, N ,N( alkyleneoxide)-carbonyl;
dimethylaminomethyl,
carboxamide,
with the further proviso that when R 2 and R 3 are unsubN-methylcarboxamide, N,N-dimethylcarboxamide, acetyl,
stituted phenyl groups or substituted phenyl groups
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl,
having an alkyl, alkoxy, chlorine or CF 3 as substituents
1
1
2
2
and X - Y and X - Y are saturated nitrogen-carbon 10 methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio,
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo,
bonds, X 1 and X 2 cannot be C=O; and
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl,
with the further proviso that when X 1 - Y 1 and X 2 - Y 2
1
2
ureido,
azido, isocyanate, thioisocyanate, hydroxylamino
are saturated carbon-carbon bonds, X and X cannot
and nitroso.
be CH 2 or CH=CH, and Y 1 and Y 2 cannot be CH 2 or
33. The compound of claim 24, wherein the saturated
CH=CH, C=O or CHOH;
15
1
1
2
2
hydrocarbon
ring includes cyclobutane, cyclopentane,
with the further proviso that when X -Y and X -Y
cyclohexane, cycloheptane or cyclooctane; the unsaturated
are carbon-carbon double bonds, R 2 and R 3 cannot be
hydrocarbon ring includes benzene, cyclopentene,
a saturated or unsaturated hydrocarbon ring with an
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene;
ortho-, meta- or para substituted moiety selected from
the group consisting of hydrogen, methyl, ethyl, C3 -C 7 20 the nitrogen containing heterocyclic moiety includes
azetine, piperdine, piperazine, pyrazine, pyrazole,
straight chain or branched alkyl, C3 -C 6 cycloalkyl,
pyrazolidine, imidazole imidazoline, pyrimidine, hexavinyl, allyl, C 4 -C 7 alkenyl, benzyl, phenylethyl,
N-methylamino, N,N-dimethylamino, carboxylate,
hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3me th ylc arb oxyl ate,
e th ylc arb o xyl ate,
triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen
p ropylc arb oxyla te, isop ropylcarb oxyla te, 25 containing heterocyclic moiety includes furan,
carboxaldehyde, acetoxy, propionyloxy,
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran,
isopropionyloxy, cyano, aminomethyl,
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin; the sulfur conN-methylaminomethyl, N,N-dimethylaminomethyl,
taining heterocyclic moiety includes thietane, thiophene,
carboxamide, N -methylcarboxamide, N ,Nthiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3dimethylcarboxamide, acetyl, propionyl, formyl, 30 dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2benzoyl, sulfate, methylsulfate, hydroxyl, methoxy,
dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium; the
ethoxy, propoxy, isopropoxy, thiol, methylthio,
selenium containing heterocyclic moiety includes seleethylthio, propiothiol, fiuoro, chloro, bromo, iodo,
nophene; the mixed heterocycic moiety includes
trifiuoromethyl, propargyl, nitro, carbamoyl, ureido,
thiazolidine,
thiazole or oxazin; and the substituent for the
azido, isocyanate, thioisocyanate, hydroxylamino, and 35
substituted benzene includes at least one member selected
nitroso; and with the further proviso that R 2 and R 3 do
from the group consisting of methyl, ethyl, propyl,
not represent N,N'-bis(2,3,5,6,8,9,11,12-octahydro-1,4,
isopropyl, butyl, sec-butyl, isobutyl, amino,
7,1 0, 13-benzopentaoxacyclopentadecin-15-yl).
N-methylamino, N,N-dimethylamino, carboxylate,
25. The compound of claim 24, wherein the saturated
hydrocarbon ring includes cyclobutane, cyclopentane, 40 methylcarboxylate, ethylcarboxylate, propylcarboxylate,
isopropylcarboxylate, carboxaldehyde, acetoxy,
cyclohexane, cycloheptane or cyclooctane.
propionyloxy, isopropionyloxy, cyano, aminomethyl,
26. The compound of claim 24, wherein the unsaturated
hydrocarbon ring includes benzene, cyclopentene,
N -methylaminomethyl, N,N -dimethylaminomethyl,
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene.
carboxainide, N -methylcarboxamide, N ,N27. The compound of claim 24, wherein the nitrogen 45 dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl,
containing heterocyclic moiety includes azetine, piperidine,
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy,
piperazine, pyrazine, pyrazole, pyrazolidine, imidazole
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro,
imidazoline, pyrimidine, hexa-hydropyrimidine, pyrrole,
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl,
pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate,
or pyridazine.
50
hydroxylamino, and nitroso.
28. The compound of claim 24, wherein the oxygen
34. The compound of claim 24, wherein when either
containing heterocyclic moiety includes furan,
X 1 - Y 1 or X 2 - Y 2 is a saturated carbon-carbon bond, Y 1 or
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran,
Y 2 represents CH 2 , CH-OH, CHO-alkyl where said alkyl
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin.
is a lower straight chain or branched alkyl, CH-OS0 2 29. The compound of claim 24, wherein the unsaturated 55
C6H5, CH-OS0 2 -p-C 6H 4 CH 3 , CH-SH, C 6H 5-SH,
sulfur containing heterocyclic moiety includes thietane,
CH-S-alkyl
where said alkyl is a lower straight chain or
thiophene, thiophane, 2,5-dihydrothiophene, 1,3branched alkyl, CH-N0 2 , CH-CF 3 , CH-NHOH,
dithiolylium, 1,3-dithiolane, 1,2-dithiolylium, 1,2CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I,
dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4-dithiane, or
thiopyranylium.
60 CH-NH 2 , CH-NH-alkyl where said alkyl is a lower
straight chain or branched alkyl, CH-N(alkyl) 2 alkyl where
30. The compound of claim 24, wherein the selenium
said alkyl is a lower straight chain or branched alkyl,
containing heterocyclic moiety is selenophene.
CH-OCONH 2 , CH-OCONH-alkyl where said alkyl is a
31. The compound of claim 24, wherein the mixed
heterocyclic moiety is thiazolidine, thiazole or oxazin.
lower straight chain or branched alkyl, CH-OCON(alkyl) 2
32. The compound of claim 24, wherein the substituted 65 where said alkyl is a lower straight chain or branched alkyl,
benzene includes at least one substituent selected from the
CH-N 3 , C=O or C=S; CH-0-phenyl, substituted
CH-0- phenyl where the substituent is at least one
group consisting of methyl, ethyl, propyl, isopropyl, butyl,
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member selected from the group consisting of methyl, ethyl,
36. The method of claim 34, wherein the pharmaceutical
propyl, isopropyl, butyl, sec-butyl, isobutyl, amino,
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate,
N -methylamino, N,N -dimethylamino, carboxylate,
citrate, fumarate and tartrate salts of said compound.
methylcarboxylate, ethylcarboxylate, propylcarboxylate,
37. The compound of claim 24, wherein said lower
isopropylcarboxylate, carboxaldehyde, acetoxy, 5 straight chain or branched alkyl contains one to seven
propionyloxy, isopropionyloxy, cyano, aminomethyl,
carbon atoms.
N -methylaminomethyl, N ,N -dimethylaminomethyl,
38. The method of claim 37, wherein said alkyl is methyl
carboxamide, N-methylcarboxamide, N,Nor ethyl.
dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl,
39. The method of claim 34, wherein said lower straight
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 10
chain or branched alkyl contains one to seven carbon atoms.
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro,
40. The method of claim 39, wherein said alkyl is methyl
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl,
or ethyl.
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate,
41. The compound of claim 24, wherein said compound
hydroxylamino, and nitroso; or a hydrocarbon or heterocyclic ring comprising pyridyl, furanyl, naphthyl, thiazole, 15 is cis-2S,6R,8S-2-[ 6-~-para-toluenesulfonyloxyphenethyl)1-methyl-2-piperidyl]-acetophenone.
selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole,
42. The compound of claim 24, wherein said compound
imidazoline, pyrimidine, pyridazine or triazine.
is cis-2S,6R-N-methyl-6-[1-(2-hydroxy-2-phenyl)ethyl ]-235. The compound of claim 24, wherein the pharmaceuphenylethylpiperidine.
tical salts are hydrochloride, hydrobromide, sulfate,
hydrosulfate, citrate, fumarate and tartrate salts of said 20
compound.
* * * * *

